

# Maximilian Tscharre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6829118/publications.pdf>

Version: 2024-02-01

25  
papers

242  
citations

1040056

9  
h-index

1058476

14  
g-index

26  
all docs

26  
docs citations

26  
times ranked

435  
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet activation and aggregation in different centrifugal-flow left ventricular assist devices. <i>Platelets</i> , 2022, 33, 249-256.	2.3	6
2	Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 782602.	2.4	5
3	Growth Differentiation Factor-15 Correlates Inversely with Protease-Activated Receptor-1-Mediated Platelet Reactivity in Patients with Left Ventricular Assist Devices. <i>Pharmaceuticals</i> , 2022, 15, 484.	3.8	4
4	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1183-1190.	2.6	1
5	Effect of marathon and ultra-marathon on inflammation and iron homeostasis. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2021, 31, 542-552.	2.9	9
6	Mean Corpuscular Volume Predicts Adverse Outcomes Following Peripheral Angioplasty With Stenting and Is Associated With On-Treatment Platelet Reactivity. <i>Angiology</i> , 2021, 72, 16-23.	1.8	3
7	Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. <i>Atherosclerosis</i> , 2021, 339, 12-19.	0.8	4
8	Response to: "Arrhythmia paradox in patients with familial hypercholesterolemia". <i>Journal of Clinical Lipidology</i> , 2020, 14, 154-155.	1.5	0
9	Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2020, 196, 31-37.	1.7	6
10	Novel Antiplatelet Agents in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 191-200.	2.0	28
11	Impact of ultra-marathon and marathon on biomarkers of myocyte necrosis and cardiac congestion: a prospective observational study. <i>Clinical Research in Cardiology</i> , 2020, 109, 1366-1373.	3.3	6
12	Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13157.	3.4	18
13	A Sex-Specific Analysis of the Predictive Value of Troponin I and T in Patients With and Without Diabetes Mellitus After Successful Coronary Intervention. <i>Frontiers in Endocrinology</i> , 2019, 10, 105.	3.5	6
14	Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2019, 119, 340-347.	3.4	14
15	Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Clinical Lipidology</i> , 2019, 13, 115-122.	1.5	11
16	Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis. <i>Clinical Research in Cardiology</i> , 2019, 108, 749-762.	3.3	16
17	Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Atherosclerosis</i> , 2018, 270, 173-179.	0.8	46
18	YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients. <i>Atherosclerosis</i> , 2018, 274, 152-156.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Lowering blood pressure in primary care in Vienna (LOW-BP-VIENNA). Wiener Klinische Wochenschrift, 2018, 130, 698-706.	1.9	2
20	Epicardial adipose tissue and cardiovascular outcome in patients with acute coronary syndrome undergoing percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 750-752.	1.0	11
21	Impact of time of admission on short- and long-term mortality in the Vienna STEMI registry. International Journal of Cardiology, 2017, 244, 1-6.	1.7	10
22	Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. PLoS ONE, 2017, 12, e0179349.	2.5	8
23	Dual antiplatelet therapy: short or long after acute coronary syndrome?. Signa Vitae, 2017, 13, .	0.3	0
24	Awareness, treatment, and control of hypertension in Austria. Journal of Hypertension, 2016, 34, 1432-1440.	0.5	13
25	Systematic screening for cardiovascular risk at pharmacies. Open Heart, 2016, 3, e000497.	2.3	7